Live attenuated vaccine for the prevention of varicella-zoster virus infection: does it work, is it safe and do we really need it in the UK?

References

1. Ampofo, K., Saiman, L., LaRussa, P., Steinberg, S., Annunziato, P. & Gershon, A. ( 2002;). Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis 34, 774–779.[CrossRef]
   [Google Scholar]
2. Arvin, A. M. & Gershon, A. A. ( 1996;). Live attenuated varicella vaccine. Annu Rev Microbiol 50, 59–100.[CrossRef]
   [Google Scholar]
3. Asano, Y., Suga, S., Yoshikawa, T., Kobayashi, I., Yazaki, T., Shibata, M., Tsuzuki, K. & Ito, S. ( 1994;). Experience and reason: twenty year follow up of protective immunity of the Oka live varicella vaccine. Pediatrics 94, 524–526.
   [Google Scholar]
4. Black, S., Shinefield, H., Ray, P., Lewis, E., Hansen, J., Schwalbe, J., Coplan, P., Sharrar, R. & Guess, H. ( 1999;). Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 18, 1041–1046.[CrossRef]
   [Google Scholar]
5. Brisson, M. & Edmunds, W. J. ( 2002;). The cost-effectiveness of varicella vaccination in Canada. Vaccine 20, 1113–1125.[CrossRef]
   [Google Scholar]
6. Brisson, M., Edmunds, W. J., Gay, N. J., Law, B. & De Serres, G. ( 2000;). Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine 18, 2775–2778.[CrossRef]
   [Google Scholar]
7. Brisson, M., Gay, N. J., Edmunds, W. J. & Andrews, N. J. ( 2002;). Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 20, 2500–2507.[CrossRef]
   [Google Scholar]
8. Clements, D. A., Moreira, S. P., Coplan, P. M., Bland, C. L. & Walter, E. B. ( 1999;). Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr Infect Dis J 18, 1047–1050.[CrossRef]
   [Google Scholar]
9. Edmunds, W. J. & Brisson, M. ( 2002;). The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 44, 211–219.[CrossRef]
   [Google Scholar]
10. Garnett, G. P. & Grenfell, B. T. ( 1992;). The epidemiology of varicella-zoster virus infections: a mathematical model. Epidemiol Infect 108, 495–511.[CrossRef]
    [Google Scholar]
11. Gershon, A. A. ( 1995;). Varicella-Zoster virus: prospects for control. Adv Pediatr Infect Dis 10, 93–123.
    [Google Scholar]
12. Gershon, A. A., LaRussa, P., Steinberg, S., Mervish, N., Lo, S. H. & Meier, P. ( 1996;). The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 173, 450–453.[CrossRef]
    [Google Scholar]
13. Gray, A. M., Fenn, P., Weinberg, J., Miller, E. & McGuire, A. ( 1997;). An economic analysis of varicella vaccination for health care workers. Epidemiol Infect 119, 209–220.[CrossRef]
    [Google Scholar]
14. Hardy, I., Gershon, A. A., Steinberg, S. P. & LaRussa, P. ( 1991;). The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N Engl J Med 325, 1545–1550.[CrossRef]
    [Google Scholar]
15. Johnson, C. E., Stancin, T., Fattlar, D., Rome, L. P. & Kumar, M. L. ( 1997;). A long–term prospective study of varicella vaccine in healthy children. Pediatrics 100, 761–766.[CrossRef]
    [Google Scholar]
16. Kappagoda, C., Shaw, P., Burgess, M. & Cramer, L. ( 1999;). Varicella vaccine in non-immune household contacts of children with cancer or leukaemia. J Paediatr Child Health 35, 341–345.[CrossRef]
    [Google Scholar]
17. Kuter, B. J., Weibel, R. E., Guess, H. A. & 7 other authors ( 1991;). Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9, 643–647.[CrossRef]
    [Google Scholar]
18. LaRussa, P., Steinberg, S. & Gershon, A. A. ( 1996;). Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J Infect Dis 174 (Suppl.), S320–S323.[CrossRef]
    [Google Scholar]
19. Oxman, M. N. ( 1995;). Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 45 (Suppl.), S41–S46.[CrossRef]
    [Google Scholar]
20. ACIP ( 1999;). Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 48 (RR- 6 ), 1–5.
    [Google Scholar]
21. Seward, J., Watson, B. M., Peterson, C. L. & 9 other authors ( 2002;). Varicella disease after introduction of varicella vaccine the United States 1995–2000. JAMA 287, 606–611.[CrossRef]
    [Google Scholar]
22. Sharrar, R. G., LaRussa, P., Galea, S. A., Steinberg, S. P., Sweet, A. R., Keatley, R. M., Wells, M. E., Stephenson, W. P. & Gershon, A. A. ( 2000;). The postmarketing safety profile of varicella vaccine. Vaccine 19, 916–923.[CrossRef]
    [Google Scholar]
23. Varis, T. & Veskari, T. ( 1996;). Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 174, S330–S334.[CrossRef]
    [Google Scholar]
24. Vazquez, M., LaRussa, P. S., Gershon, A. A., Steinberg, S. P., Freudigman, K. & Shapiro, E. D. ( 2001;). The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 344, 955–960.[CrossRef]
    [Google Scholar]
25. Weibel, R. E., Neff, B. J., Kuter B. J. & 7 other authors ( 1984;). Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 310, 1409–1411.[CrossRef]
    [Google Scholar]
26. White, C. J., Kuter, B. J., Hildebrand, C. S. & 7 other authors ( 1991;). Varicella vaccine (VARIVAX) in healthy children and adolescents results from clinical trials, 1987 to 1989. Pediatrics 87, 604–610.
    [Google Scholar]